Human Papillomavirus Infection Clinical Trial
— ING-HPV-1Official title:
Open Controlled Randomized Study of the Efficacy and Safety of Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts (Phase III)
Verified date | November 2021 |
Source | SPP Pharmaclon Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this study is to evaluate the effectiveness of destructive therapy for anogenital warts in combination with the use of Ingaron in comparison with destructive therapy.
Status | Completed |
Enrollment | 30 |
Est. completion date | July 15, 2010 |
Est. primary completion date | June 30, 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: 1. Patients of both sexes aged 18 to 50 years with a diagnosis of "Anogenital warts". 2. The diagnosis "Anogenital warts" was made for the first time at least one year before inclusion in the study. 3. During the last year prior to inclusion in the study, the patient had at least 2 recurrences of anogenital warts. 4. The diagnosis is confirmed by the detection of HPV by polymerase chain reaction (PCR). 5. Negative pregnancy test in women. 6. Availability of written informed consent to participate in the study. Exclusion Criteria: 1. Positive test results for syphilis, hepatitis (HbsAg, anti-HCV), HIV infection, gonococcal infection, urogenital trichomoniasis, chlamydial infection, inflammatory diseases of the urogenital system caused by genital mycoplasmas. 2. Unsystematic use of barrier methods of contraception. 3. Pregnancy and lactation. 4. Known allergic reactions to interferons and / or other significant allergic diseases. 5. Any immunotropic therapy within the last 6 weeks prior to enrollment in the study. 6. The need to take drugs prohibited during the study. 7. Condition after organ transplantation, constant intake of immunosuppressive drugs. 8. Severe pathology from the cardiovascular system (uncontrolled arterial hypertension, unstable angina pectoris, congestive heart failure, cardiac arrhythmias), a history of myocardial infarction or cerebrovascular accident within the last 6 months. 9. Severe pathology on the part of the liver (increased content of AST, ALT 2 times higher than the upper limit of the norm, the content of total bilirubin> 2 mg / dL), kidney (content of creatinine> 1.5 mg / dL); signs of hepatic and / or renal failure. 10. The presence of severe pathology on the part of the respiratory system, gastrointestinal tract, hematopoietic system. 11. Other serious (acute or chronic) pathological conditions, including mental illness, as well as abnormalities in laboratory parameters, which, in the opinion of the investigator, may increase the risk associated with participation in the study or affect the interpretation of efficacy and safety data obtained in this research. 12. Alcohol and / or drug dependence. 13. Participation in other clinical trials in the last three months prior to inclusion. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | State scientific center of a dermatovenereology and cosmetology | Moscow |
Lead Sponsor | Collaborator |
---|---|
SPP Pharmaclon Ltd. |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recurrence of anogenital warts | Number of participants with recurrent anogenital warts | Day 11 | |
Primary | Recurrence of anogenital warts | Number of participants with recurrent anogenital warts | Day 40 | |
Primary | Recurrence of anogenital warts | Number of participants with recurrent anogenital warts | Day 100 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05458869 -
Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
|
||
Completed |
NCT01932697 -
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT03265743 -
HPV Vaccination in Women With Cystic Fibrosis
|
N/A | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A | |
Completed |
NCT06199128 -
Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients
|
||
Active, not recruiting |
NCT01824537 -
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
|
Phase 4 | |
Unknown status |
NCT01087164 -
Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers
|
N/A | |
Completed |
NCT01265212 -
Prevalence of Human Papillomavirus in Men Living in the Northern Plains
|
N/A | |
Terminated |
NCT01082861 -
Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination
|
Phase 4 | |
Completed |
NCT00572832 -
Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
|
N/A | |
Completed |
NCT03158220 -
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
|
Phase 3 | |
Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
Completed |
NCT05680454 -
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
|
Phase 1 | |
Completed |
NCT04133610 -
HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs
|
N/A | |
Completed |
NCT00988884 -
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
|
Phase 3 | |
Not yet recruiting |
NCT05981807 -
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
|
||
Recruiting |
NCT03302858 -
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand
|
Phase 2 | |
Completed |
NCT01694875 -
Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System
|
N/A | |
Completed |
NCT01205412 -
An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain
|
N/A |